BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.71.

BCRX has been the topic of a number of recent analyst reports. ValuEngine cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co lifted their target price on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 6th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $5.00 to $7.00 in a research note on Wednesday, September 6th. Finally, Royal Bank of Canada initiated coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 target price on the stock.

In related news, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Fred E. Cohen sold 54,250 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares in the company, valued at $941,237.20. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in BCRX. Legal & General Group Plc raised its stake in BioCryst Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 860 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at about $132,000. SG Americas Securities LLC raised its stake in BioCryst Pharmaceuticals by 98.6% in the 3rd quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 13,402 shares during the period. Janney Montgomery Scott LLC raised its stake in BioCryst Pharmaceuticals by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 1,500 shares during the period. Finally, Pacad Investment Ltd. bought a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at about $196,000. Institutional investors and hedge funds own 84.69% of the company’s stock.

BioCryst Pharmaceuticals (NASDAQ BCRX) traded up $0.15 during midday trading on Monday, hitting $5.00. The stock had a trading volume of 3,693,202 shares, compared to its average volume of 935,574. BioCryst Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The company had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) EPS. sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.71 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Analysts Set BioCryst Pharmaceuticals, Inc. (BCRX) Price Target at $9.71” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/analysts-set-biocryst-pharmaceuticals-inc-bcrx-price-target-at-9-71/1768679.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.